Companies › Xerient Pharma
1 active drug program in 1 registered trial: 1 Phase 1; Oncology; next expected readout Jul 2029.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| XER-001 (Amifostine for nasoduodenal delivery) Radioprotective agent; aminothiol that scavenges free radicals generated by radiation | – | Phase 1 | Locally Advanced Pancreatic Adenocarcinoma | Jul 2029 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07157033 | XER-001 (Amifostine for nasoduodenal delivery) | Phase 1 | Locally Advanced Pancreatic Adenocarcinoma | Oncology | Jul 2029 |
No annotated target.
–
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.